病例报告：S-1/奥沙利铂方案联合曲妥珠单抗和替雷利珠单抗治疗局部晚期胃癌患者后的病理完全缓解
Case report: pathological complete response after S-1/oxaliplatin regimen combined with trastuzumab and tislelizumab in patients with locally advanced gastric cancer.
作者信息
Zhu Chenglou, Da Mingxu, Li Yaoqi, Peng Lingzhi
机构信息
The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Department of Surgical Oncology, Gansu Provincial Hospital, Lanzhou, China.
出版信息
Front Oncol. 2024 Sep 5;14:1425572. doi: 10.3389/fonc.2024.1425572. eCollection 2024.
BACKGROUND
The efficacy of a regimen combining Tegafur, Gimeracil and Oteracil Potassium Capsules (S-1), oxaliplatin (SOX) with trastuzumab and tislelizumab chemotherapy for advanced gastric cancer (GC) has not been reported.
CASE SUMMARY
A 56-year-old male was diagnosed with GC combined with peripheral lymph node metastasis. The patient received neoadjuvant chemotherapy, including SOX, tislelizumab and trastuzumab. After 4 cycles of chemotherapy, the tumor shrank significantly, and radical surgery was performed with good clinical results. To date, the patient has been followed up for 6 months with no significant side effects.
CONCLUSION
In this study, the patient received combination chemotherapy with SOX trastuzumab and tislelizumab and successfully underwent radical surgery with good clinical outcomes. Combined SOX with trastuzumab and tislelizumab may be an effective neoadjuvant chemotherapy regimen.
背景
替吉奥胶囊（S-1）、奥沙利铂（SOX）联合曲妥珠单抗和替雷利珠单抗化疗方案用于晚期胃癌（GC）的疗效尚未见报道。
病例摘要
一名56岁男性被诊断为GC合并周围淋巴结转移。该患者接受了新辅助化疗，包括SOX、替雷利珠单抗和曲妥珠单抗。化疗4个周期后，肿瘤明显缩小，并进行了根治性手术，临床效果良好。迄今为止，该患者已随访6个月，无明显副作用。
结论
在本研究中，患者接受了SOX、曲妥珠单抗和替雷利珠单抗联合化疗，并成功进行了根治性手术，临床效果良好。SOX联合曲妥珠单抗和替雷利珠单抗可能是一种有效的新辅助化疗方案。
Zotero 插件